Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
Inhibikase Therapeutics (Nasdaq: IKT), a clinical-stage pharmaceutical company focusing on protein kinase inhibitor therapeutics for Parkinson's disease and related disorders, has announced its schedule for reporting second quarter 2024 financial results. The company will release its financial report on August 14, 2024, after U.S. markets close. Following this, Inhibikase will host a conference call and webcast on August 15, 2024, at 8:00 a.m. ET to provide a corporate update and review the financial results.
Investors and interested parties can access the conference call by dialing 1-877-407-0789 (U.S.) or 1-201-689-8562 (International). A live webcast will also be available through a link on the company's website. The webcast will be archived on Inhibikase's website for approximately 90 days after the call.
Inhibikase Therapeutics (Nasdaq: IKT), un'azienda farmaceutica in fase clinica che si concentra su terapie inibitorie delle chinasi per il Parkinson e disturbi correlati, ha annunciato il programma per la comunicazione dei risultati finanziari del secondo trimestre 2024. L'azienda pubblicherà il suo rapporto finanziario il 14 agosto 2024, dopo la chiusura dei mercati statunitensi. Successivamente, Inhibikase ospiterà una conferenza telefonica e una diretta web il 15 agosto 2024, alle 8:00 ET per fornire aggiornamenti aziendali e rivedere i risultati finanziari.
Investitori e parti interessate possono accedere alla conferenza telefonica chiamando 1-877-407-0789 (USA) o 1-201-689-8562 (Internazionale). Sarà disponibile anche una diretta web tramite un link sul sito dell'azienda. La diretta sarà archiviata sul sito di Inhibikase per circa 90 giorni dopo la chiamata.
Inhibikase Therapeutics (Nasdaq: IKT), una compañía farmacéutica en etapa clínica que se centra en terapias inhibidoras de quinasas para la enfermedad de Parkinson y trastornos relacionados, ha anunciado su cronograma para informar sobre los resultados financieros del segundo trimestre de 2024. La compañía publicará su informe financiero el 14 de agosto de 2024, después del cierre de los mercados en EE. UU. Después de esto, Inhibikase llevará a cabo una conferencia telefónica y una transmisión web el 15 de agosto de 2024, a las 8:00 a.m. ET para proporcionar una actualización corporativa y revisar los resultados financieros.
Los inversores y partes interesadas pueden acceder a la conferencia telefónica marcando 1-877-407-0789 (EE. UU.) o 1-201-689-8562 (Internacional). También habrá una transmisión web en vivo a través de un enlace en el sitio web de la compañía. La transmisión se archivará en el sitio de Inhibikase durante aproximadamente 90 días después de la llamada.
Inhibikase Therapeutics (Nasdaq: IKT)는 파킨슨병 및 관련 장애를 위한 단백질 키나제 억제제를 중심으로 하는 임상 단계 제약회사로, 2024년 2분기 재무 결과 보고 일정을 발표했습니다. 회사는 2024년 8월 14일에 미국 시장이 마감된 후 재무 보고서를 발표할 예정입니다. 이후 Inhibikase는 2024년 8월 15일 오전 8:00 ET에 기업 업데이트를 제공하고 재무 결과를 검토하기 위해 전화 회의 및 웹캐스트를 개최할 것입니다.
투자자 및 이해 관계자는 1-877-407-0789 (미국) 또는 1-201-689-8562 (국제)로 전화하여 회의에 참여할 수 있습니다. 또한 회사 웹사이트의 링크를 통해 생중계 웹캐스트도 제공될 예정입니다. 웹캐스트는 호출 후 약 90일 동안 Inhibikase의 웹사이트에 보관됩니다.
Inhibikase Therapeutics (Nasdaq: IKT), une entreprise pharmaceutique en phase clinique axée sur les thérapies par inhibiteurs de kinases pour la maladie de Parkinson et les troubles connexes, a annoncé son calendrier pour la publication des résultats financiers du deuxième trimestre 2024. L'entreprise publiera son rapport financier le 14 août 2024, après la fermeture des marchés américains. Par la suite, Inhibikase organisera une conférence téléphonique et un webinaire le 15 août 2024 à 8:00 AM ET pour fournir une mise à jour sur l'entreprise et examiner les résultats financiers.
Les investisseurs et les parties intéressées peuvent accéder à la conférence téléphonique en composant le 1-877-407-0789 (USA) ou le 1-201-689-8562 (International). Un webinaire en direct sera également disponible via un lien sur le site Web de l'entreprise. Le webinaire sera archivé sur le site d'Inhibikase pendant environ 90 jours après l'appel.
Inhibikase Therapeutics (Nasdaq: IKT), ein Unternehmen in der klinischen Phase, das sich auf die Therapie mit Protein-Kinase-Inhibitoren bei Parkinson-Krankheit und verwandten Erkrankungen konzentriert, hat seinen Zeitplan zur Berichterstattung über die Finanzergebnisse des zweiten Quartals 2024 bekannt gegeben. Das Unternehmen wird seinen Finanzbericht am 14. August 2024 nach dem Handelsende der US-Märkte veröffentlichen. Im Anschluss daran wird Inhibikase am 15. August 2024 um 8:00 Uhr ET eine Telefonkonferenz und ein Webcast abhalten, um ein Unternehmensupdate zu geben und die finanziellen Ergebnisse zu überprüfen.
Investoren und interessierte Parteien können an der Telefonkonferenz teilnehmen, indem sie 1-877-407-0789 (USA) oder 1-201-689-8562 (International) anrufen. Ein Live-Webcast wird ebenfalls über einen Link auf der Unternehmenswebsite verfügbar sein. Der Webcast wird etwa 90 Tage nach dem Anruf auf der Website von Inhibikase archiviert.
- None.
- None.
BOSTON and ATLANTA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it will report financial results for the second quarter ended June 30, 2024, on Wednesday, August 14, 2024, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET on Thursday, August 15, 2024, to provide a corporate update and review the financial results.
The conference call can be accessed by dialing 1-877-407-0789 (United States) or 1-201-689-8562 (International) and referencing Inhibikase Therapeutics. A live webcast may be accessed using the link here, or by visiting the investors section of the Company's website at www.inhibikase.com. After the live webcast, the event will be archived on Inhibikase's website for approximately 90 days after the call.
About Inhibikase (www.inhibikase.com)
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Inhibikase's multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program risvodetinib, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases. Its multi-therapeutic pipeline is pursuing Parkinson's-related disorders of the brain and GI tract, orphan indications related to Parkinson's disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate that the Company believes will provide a better patient experience with fewer on-dosing side-effects. The Company's RAMP™ medicinal chemistry program has identified several follow-on compounds to risvodetinib that could potentially be applied to other cognitive and motor function diseases of the brain. Inhibikase is headquartered in Atlanta, Georgia with offices in Lexington, Massachusetts.
Social Media Disclaimer
Investors and others should note that the Company announces material financial information to investors using its investor relations website, press releases, SEC filings and public conference calls and webcasts. The Company intends to also use X, Facebook, LinkedIn and YouTube as a means of disclosing information about the Company, its services and other matters and for complying with its disclosure obligations under Regulation FD.
Contacts:
Company Contact:
Milton H. Werner, PhD
President & CEO
678-392-3419
info@inhibikase.com
Investor Relations:
Alex Lobo
Precision AQ
Alex.lobo@precisionaq.com
FAQ
When will Inhibikase Therapeutics (IKT) report its Q2 2024 financial results?
What is the date and time of Inhibikase Therapeutics' (IKT) Q2 2024 earnings call?
How can investors access Inhibikase Therapeutics' (IKT) Q2 2024 earnings call?
What is the main focus of Inhibikase Therapeutics (IKT)?
